SCHEMBL6884583

SCHEMBL6884583

Cc1cccc(-c2c(-c3ccc(N)c(-c4ccccc4)c3-c3cccc(C)c3)ccc(N)c2-c2ccccc2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 2/20 0.44
HDAC2 Q92769 1/20 0.43
RAB9A P51151 5/20 0.43
NPC1 O15118 4/20 0.43
KMT2A Q03164 3/20 0.43
CNR2 P34972 4/20 0.42
CNR1 P21554 3/20 0.42
ADORA2A P29274 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
TSHR P16473 2/20 0.41
HPGD P15428 2/20 0.41
ALDH1A1 P00352 3/20 0.41
HEXA P06865 1/20 0.41
HEXB P07686 1/20 0.41
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
NPSR1 Q6W5P4 1/20 0.40
DPP4 P27487 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4058897 0.95 RAB9A (0.46) ADORA1HDAC2RAB9ANPC1KMT2A
SCHEMBL6933399 0.93 HDAC2 (0.48) ADORA1HDAC2RAB9ANPC1KMT2A
Ammonia Solution, Strong SCHEMBL1411404 0.92 RAB9A (0.45) ADORA1HDAC2RAB9ANPC1KMT2A
SCHEMBL6930975 0.87 RAB9A (0.52) ADORA1HDAC2RAB9ANPC1KMT2A
SCHEMBL29633828 0.83 RAB9A (0.49) ADORA1HDAC2RAB9ANPC1KMT2A
SCHEMBL1247441 0.83 RAB9A (0.49) ADORA1HDAC2RAB9ANPC1KMT2A
SCHEMBL29416551 0.83 RAB9A (0.49) ADORA1HDAC2RAB9ANPC1KMT2A
SCHEMBL297637 0.83 ALDH1A1 (0.48) KMT2AADORA2ASMN1; SMN2HPGDALDH1A1
SCHEMBL7164278 0.83 ALDH1A1 (0.42) ADORA1HDAC2RAB9ANPC1KMT2A
SCHEMBL2732779 0.82 HEXA (0.40) ADORA1HDAC2RAB9ANPC1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6824890-B2 TOPOLOGICAL STRATEGY FOR DESIGNING AMORPHOUS MOLECULAR SOLIDS FOR FORMING THIN FILMS IN OPTOELECTRONIC DEVICES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2004-11-30 US disclosed
US-20030055278-A1 Soluble tetrahedral compounds for use in electroluminescent devices NATIONAL SCIENCE FOUNDATION 2003-03-20 US disclosed
WO-2001083410-A1 SOLUBLE TETRAHEDRAL COMPOUNDS FOR USE IN ELECTROLUMINESCENT DEVICES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2001-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055278-A1 Soluble tetrahedral compounds for use in electroluminescent devices PAX3, EPCAM, PAXBP1 ADORA1 4607/4885HDAC2 3012/4885RAB9A 869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.